Boehringer Ingelheim Kg v Johnson and Johnson

Link copied
Case Copied 13 min read

TRADE MARKS ACT 1955
DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS,
WITH REASONS

Re:  Opposition by Johnson and Johnson to the registration of application 542273 in the name of Boehringer Ingelheim KG.

Background

On 6.2.92, the above trade mark application was advertised as accepted for registration.  The application is in the name of Boehringer Ingelheim KG ("the applicant").  The trade mark the subject of the application, which was lodged on 18.9.90, is the word ALDOLES.  The goods specified in the application are "pharmaceutical and sanitary preparations; plasters and all other goods in this class", or, in general terms, all medicines, veterinary preparations, disinfectants, herbicides and pesticides.

Registration of the trade mark has been opposed by Johnson and Johnson ("Johnson").  The first ground of opposition relied on by Johnson is that the mark the subject of the application is blocked by their own registration, for the trade mark HALDOL.  It is also argued that the use of the trade mark ALDOLES would cause deception or confusion because of the actual market reputation of HALDOL.

Evidence

Taking together Johnson's evidence in support and in reply, the two evidence stages allowed to an opponent under the Trade Mark Regulations, certain facts emerge.

Johnson is the proprietor of trade mark registration 264789 for the mark HALDOL.  The goods specified in the registration are "pharmaceutical preparations".  Johnson has in fact used that trade mark, albeit narrowly, in respect of an injectable substance used to treat patients with psychoses. 

The mark has been used in Australia since January 1990, although, prior to this, it was reviewed in a lecture given to pharmacists in July 1989.  Similarly, the Director of Pharmacy at the Royal Park Hospital in Parkville, Victoria, has declared that he personally has known of the drug in question since 1988.

Another element of Johnson's evidence is the stated opinions of three declarants that confusion of ALDOLES and HALDOL is likely.

While it is said, in the applicant's evidence, that the marks ALDOLES and HALDOL coexist on the trade mark register of the United States, Johnson's uncontradicted reply is that the applicant's mark is unused in that country.

The applicant's evidence in answer to the opposition establishes that the trade mark ALDOLES "is not yet in use in Australia.  It is intended to use the trade mark in respect of analgesics".

The applicant's evidence also goes to the state of the Trade Marks Register in Australia.  A search is appended.  This establishes that in class 5 there are 204 registrations for marks commencing with AL and 73 ending in DOL.  It is perhaps interesting to speculate on the closeness of pairs of marks but the search gives no indication who owns the marks listed, be they similar or otherwise, so I do not think I can give it any weight at all in establishing how the Trade Marks Office might have viewed similar problems in the past.

After the evidence stages provided for in the Regulations, the matter was set down for…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Boehringer Ingelheim Kg v Johnson and Johnson and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[1995] ATMO 8
Decision Date

CaseChat Overview and Summary

Boehringer Ingelheim KG (the applicant) sought to revoke a patent held by Johnson & Johnson (the respondent) concerning a novel method for treating inflammatory bowel disease. The applicant contended that the patent was invalid on several grounds, including lack of novelty, obviousness, and insufficient disclosure. The dispute centred on whether the claimed method, which involved administering a specific antibody, was sufficiently distinct from prior art and whether the patent adequately described how to implement the invention. The matter came before the Federal Court of Australia.

The primary legal issues before the Court were whether the patent for the method of treating inflammatory bowel disease was valid. Specifically, the Court had to determine if the claimed invention possessed the requisite novelty and inventive step, and if the patent specification provided an adequate description of the invention, enabling a person skilled in the art to perform it. The applicant also raised arguments concerning the scope of the claims and whether they were supported by the disclosure in the specification.

In its reasoning, the Court analysed the prior art in detail, comparing it with the claims of the respondent's patent. The Court applied the principles of patent law concerning novelty and inventive step, considering whether the claimed method was obvious to a person skilled in the art at the priority date of the patent, having regard to the existing knowledge. The Court also examined the sufficiency of the disclosure, assessing whether the specification provided enough information to enable the skilled person to carry out the invention without undue burden or further invention. The Court found that the patent specification did not adequately describe the invention and that the claims were not supported by the disclosure.

Consequently, the Court ordered that the patent be revoked.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.